Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

labyrinthin peptide vaccine LabVax 3(22)-23

A synthetic peptide vaccine composed of four synthetic peptide epitopes of the tumor-associated antigen (TAA) labyrinthin, with potential immunomodulating and antineoplastic activities. Upon vaccination with labyrinthin peptide vaccine LabVax 3(22)-23, the labyrinthin peptides may stimulate the immune system to mount B-cell and cytotoxic T-lymphocyte (CTL) responses against labryrinthin-expressing tumor cells. Labyrinthin is expressed on the surface of essentially all adenocarcinomas, but is not expressed in normal, healthy cells.
Synonym:LabVax
LabVax 3(22)-23
labyrinthin-targeting peptide vaccine LabVax 3(22)-23
peptide vaccine LabVax 3(22)-23
Search NCI's Drug Dictionary